AI Chat Paper
Note: Please note that the following content is generated by AMiner AI. SciOpen does not take any responsibility related to this content.
{{lang === 'zh_CN' ? '文章概述' : 'Summary'}}
{{lang === 'en_US' ? '中' : 'Eng'}}
Chat more with AI
Powered by AMiner. Clicking this button will take you away from SciOpen.
Home Brain Hemorrhages Article
PDF (1.6 MB)
Cite
EndNote(RIS) BibTeX
Collect
Submit Manuscript AI Chat Paper
Show Outline
Outline
Show full outline
Hide outline
Outline
Show full outline
Hide outline
Research Article | Open Access

Anticoagulant-associated intracerebral hemorrhage

Andrea Morottia,b( ), Joshua N. Goldsteinb,c
Stroke Unit, IRCCS Mondino Foundation, Pavia, Italy
J. P. Kistler Stroke Research Center, Massachusetts General Hospital, Harvard Medical School, Boston, USA
Department of Emergency Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, USA
Show Author Information

Abstract

Intracerebral hemorrhage (ICH) is the most dangerous complication of oral anticoagulant treatment (OAT). Up to half of patients with OAT-related ICH experience early clinical deterioration due to active bleeding, leading to hematoma enlargement. Prevention of ICH expansion is therefore one of the primary goals of acute ICH treatment. Blood pressure control and rapid reversal of coagulopathy are the mainstays of acute medical management. Specific reversal agents for vitamin K antagonists, direct thrombin inhibitors, and Factor Xa inhibitors are now available for clinical use, and may improve outcomes when given early enough in the clinical course.

Keywords

Intracerebral hemorrhageWarfarinDirect oral anticoagulantsReversal

References

1

Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM. The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med.. 2004;164: 880-884.
Crossref Google Scholar
2

Morotti A, Goldstein JN. New oral anticoagulants and their reversal agents. Curr Treat Options Neurol.. 2016;18.
Crossref Google Scholar
3

Dentali F, Riva N, Crowther M, Turpie AGG, Lip GYH, Ageno W. Efficacy and safety of the novel oral anticoagulants in atrial fibrillation: a systematic review and meta-analysis of the literature. Circulation.. 2012;126: 2381-2391.
Crossref Google Scholar
4

Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet.. 2014;383: 955-962.
Crossref Google Scholar
5

Flaherty ML, Kissela B, Woo D, et al. The increasing incidence of anticoagulant-associated intracerebral hemorrhage. Neurology.. 2007;68: 116-121.
Crossref Google Scholar
6

Ikram MA, Wieberdink RG, Koudstaal PJ. International epidemiology of intracerebral hemorrhage. Curr Atheroscler Rep.. 2012;14: 300-306.
Crossref Google Scholar
7

Schols AMR, Schreuder FHBM, van Raak EPM, et al. Incidence of oral anticoagulant-associated intracerebral hemorrhage in the Netherlands. Stroke.. 2014;45: 268-270.
Crossref Google Scholar
8

Falcone GJ, Radmanesh F, Brouwers HB, et al. APOE variants increase risk of warfarin-related intracerebral hemorrhage. Neurology.. 2014;83: 1139-1146.
Crossref Google Scholar
9

Grysiewicz R, Gorelick PB. Incidence, mortality, and risk factors for oral anticoagulant–associated intracranial hemorrhage in patients with atrial fibrillation. J Stroke Cerebrovasc Dis.. 2014;23: 2479-2488.
Crossref Google Scholar
10

Cervera Á, Amaro S, Chamorro Á. Oral anticoagulant-associated intracerebral hemorrhage. J Neurol.. 2012;259: 212-224.
Crossref Google Scholar
11

Qureshi AI, Mendelow AD, Hanley DF. Intracerebral haemorrhage. Lancet.. 2009;373: 1632-1644.
Crossref Google Scholar
12

Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges. Lancet Neurol.. 2010;9: 689-701.
Crossref Google Scholar
13

Hart RG. What causes intracerebral hemorrhage during warfarin therapy? Neurology.. 2000;55: 907-908.
Crossref Google Scholar
14

Brouwers HB, Greenberg SM. Hematoma expansion following acute intracerebral hemorrhage. Cerebrovasc Dis.. 2013;35: 195-201.
Crossref Google Scholar
15

Flibotte JJ, Hagan N, O’Donnell J, Greenberg SM, Rosand J. Warfarin, hematoma expansion, and outcome of intracerebral hemorrhage. Neurology.. 2004;63: 1059-1064.
Crossref Google Scholar
16

Falcone GJ, Biffi A, Brouwers HB, et al. Predictors of hematoma volume in deep and lobar supratentorial intracerebral hemorrhage. JAMA Neurol.. 2013;70: 988.
Crossref Google Scholar
17

Falcone GJ, Brouwers HB, Biffi A, et al. Warfarin and statins are associated with hematoma volume in primary infratentorial intracerebral hemorrhage. Neurocrit Care.. 2013: 1-8.
Crossref Google Scholar
18

Biffi A, Battey TWK, Ayres AM, et al. Warfarin-related intraventricular hemorrhage: imaging and outcome. Neurology.. 2011;77: 1840-1846.
Crossref Google Scholar
19

Pezzini A, Grassi M, Paciaroni M, et al. Antithrombotic medications and the etiology of intracerebral hemorrhage MUCH-Italy. Neurology.. 2014;82: 529-535.
Crossref Google Scholar
20

Flaherty ML, Haverbusch M, Sekar P, et al. Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care.. 2006;5: 197-201.
Crossref Google Scholar
21

Blacquiere D, Demchuk AM, Al-Hazzaa M, et al. Intracerebral hematoma morphologic appearance on noncontrast computed tomography predicts significant hematoma expansion. Stroke.. 2015;46: 3111-3116.
Crossref Google Scholar
22

Pfleger MJ, Hardee EP, Contant CF, Hayman LA. Sensitivity and specificity of fluid-blood levels for coagulopathy in acute intracerebral hematomas. AJNR Am J Neuroradiol.. 1994;15: 217-223.
Google Scholar
23

Huttner HB, Steiner T, Hartmann M, et al. Comparison of ABC/2 estimation technique to computer-assisted planimetric analysis in warfarin-related intracerebral parenchymal hemorrhage. Stroke.. 2006;37: 404-408.
Crossref Google Scholar
24

Radmanesh F, Falcone GJ, Anderson CD, et al. Risk factors for computed tomography angiography spot sign in deep and lobar intracerebral hemorrhage are shared. Stroke.. 2014;45: 1833-1835.
Crossref Google Scholar
25

Boulouis G, Morotti A, Bart Brouwers H, et al. Association between hypodensities detected by computed tomography and hematoma expansion in patients with intracerebral hemorrhage. JAMA Neurol.. 2016;73: 961-968.
Crossref Google Scholar
26

Schaefer JK, McBane RD, Wysokinski WE. How to choose appropriate direct oral anticoagulant for patient with nonvalvular atrial fibrillation. Ann Hematol.. 2016;95: 437-449.
Crossref Google Scholar
27

Siegal DM, Crowther M. Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J.. 2013;34: 489-500.
Crossref Google Scholar
28

Garcia D, Barrett YC, Ramacciotti E, Weitz JI. Laboratory assessment of the anticoagulant effects of the next generation of oral anticoagulants. J Thromb Haemost.. 2013;11: 245-252.
Crossref Google Scholar
29

Peacock WF, Rafique Z, Singer AJ. Direct-acting oral anticoagulants: practical considerations for emergency medicine physicians. Emerg Med Int.. 2016;2016: 1781684.
Crossref Google Scholar
30

Barnes GD, Kurtz B. Direct oral anticoagulants: unique properties and practical approaches to management. Heart.. 2016 Oct 15;102: 1620-1626.
Crossref Google Scholar
31

Steiner T, Weitz JI, Veltkamp R. Anticoagulant-associated intracranial hemorrhage in the era of reversal agents. Stroke.. 2017;48: 1432-1437.
Crossref Google Scholar
32

Hemphill JC, Greenberg SM, Anderson CS, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke.. 2015;46: 2032-2060.
Crossref Google Scholar
33

Frontera JA, Lewin JJ, Rabinstein AA, et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the neurocritical care society and society of critical care medicine. Neurocrit Care.. 2015: 1-41.
Crossref Google Scholar
34

Kuramatsu JB, Gerner ST, Schellinger PD, et al. Anticoagulant reversal, blood pressure levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA.. 2015;313: 824.
Crossref Google Scholar
35

Cuker A, Siegal DM, Crowther MA, Garcia DA. Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol.. 2014;64: 1128-1139.
Crossref Google Scholar
36

Heidbuchel H, Verhamme P, Alings M, et al. Updated European Heart Rhythm Association Practical Guide on the use of non-Vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace.. 2015;17: 1467-1507.
Crossref Google Scholar
37

Veltkamp R, Horstmann S. Treatment of intracerebral hemorrhage associated with new oral anticoagulant use. Clin Lab Med.. 2014;34: 587-594.
Crossref Google Scholar
38

Morishima Y, Kamisato C. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay. Am J Clin Pathol.. 2015;143: 241-247.
Crossref Google Scholar
39

Cuker A, Husseinzadeh H. Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis.. 2015: 288-294.
Crossref Google Scholar
40

Gerner ST, Kuramatsu JB, Sembill JA, et al. Association of prothrombin complex concentrate administration and hematoma enlargement in non-vitamin K antagonist oral anticoagulant-related intracerebral hemorrhage. Ann Neurol.. 2018;83: 186-196.
Crossref Google Scholar
41

Aguilar MI, Freeman WD. Treatment of coagulopathy in intracranial hemorrhage. Curr Treat Options Neurol.. 2010;12: 113-128.
Crossref Google Scholar
42

Brophy GM, Human T. Pharmacotherapy pearls for emergency neurological life support. Neurocrit Care.. 2017;27: 51-73.
Crossref Google Scholar
43

Connolly SJ, Milling TJ, Eikelboom JW, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med.. 2016;375: 1131-1141.
Crossref Google Scholar
44

Steiner T, Bösel J. Options to restrict hematoma expansion after spontaneous intracerebral hemorrhage. Stroke.. 2010;41: 402-409.
Crossref Google Scholar
45

Claude Hemphill J, Lam A. Emergency neurological life support: intracerebral hemorrhage. Neurocrit Care.. 2017;27: 89-101.
Crossref Google Scholar
46

Aguilar MI, Hart RG, Kase CS, et al. Treatment of warfarin-associated intracerebral hemorrhage: literature review and expert opinion. Mayo Clin Proc.. 2007;82: 82-92.
Crossref Google Scholar
47

Marietta M, Pedrazzi P, Girardis M, Torelli G. Intracerebral haemorrhage: an often neglected medical emergency. Intern Emerg Med.. 2007;2: 38-45.
Crossref Google Scholar
48

Steiner T, Poli S, Griebe M, et al. Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol.. 2016;15: 566-573.
Crossref Google Scholar
49

Morotti A, Goldstein JN. Diagnosis and management of acute intracerebral hemorrhage. Emerg Med Clin North Am.. 2016;34.
Crossref Google Scholar
50

Goldstein JN, Refaai MA, Milling TJ, et al. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet.. 2015;385: 2077-2087.
Crossref Google Scholar
51

Milling TJ, Refaai M, Goldstein JN, et al. Thromboembolic events after vitamin K antagonist reversal with 4-factor prothrombin complex concentrate: exploratory analyses of two randomized, plasma-controlled studies. Ann Emerg Med.. 2016 Jan;67: 96-105, e5.
Crossref Google Scholar
52

Joseph R, Burner J, Yates S, Strickland A, Tharpe W, Sarode R. Thromboembolic outcomes after use of a four-factor prothrombin complex concentrate for vitamin K antagonist reversal in a real-world setting. Transfusion.. 2016;56: 799-807.
Crossref Google Scholar
53
Ahmed N, Steiner T, Caso V, Wahlgren N. In: Recommendations from the ESO-Karolinska Stroke Update Conference, Stockholm 13–15 November 2016.
54

Eikelboom JW, Quinlan DJ, van Ryn J, et al. Idarucizumab: the antidote for reversal of dabigatran. Circulation.. 2015;132:2412-2422.
Crossref Google Scholar
55

Glund S, Stangier J, Schmohl M, et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet.. 2015;386:680-690.
Crossref Google Scholar
56

Pollack CV, Reilly PA, van Ryn J, et al. Idarucizumab for dabigatran reversal — full cohort analysis. N Engl J Med.. 2017;377:431-441.
Crossref Google Scholar
57

Heidbuchel H, Verhamme P, Alings M, et al. European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace.. 2013;15:625-651.
Crossref Google Scholar
58

Siegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis.. 2015;39:395-402.
Crossref Google Scholar
59

Levine M, Goldstein JN. Emergency reversal of anticoagulation: novel agents. Curr Neurol Neurosci Rep.. 2014;14:1-6.
Crossref Google Scholar
60

Siegal DM, Curnutte JT, Connolly SJ, et al. Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med.. 2015;373:2413-2424.
Crossref Google Scholar
61

Crowther M, Crowther MA. Antidotes for novel oral anticoagulants: current status and future potential. Arterioscler Thromb Vasc Biol.. 2015;35:1736-1745.
Crossref Google Scholar
62

Enriquez A, Lip GYH, Baranchuk A. Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants. Europace.. 2015:1-10.
Crossref Google Scholar
63

Siegal D, Lu G, Leeds JM, et al. Safety, pharmacokinetics, and reversal of apixaban anticoagulation with andexanet alfa. Blood Adv.. 2017;1:1827-1838.
Crossref Google Scholar
64

Ansell JE, Bakhru SH, Laulicht BE, et al. Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med.. 2014;371:2141-2142.
Crossref Google Scholar
65

Sullivan DW, Gad SC, Laulicht B, Bakhru S, Steiner S. Nonclinical safety assessment of PER977: a small molecule reversal agent for new oral anticoagulants and heparins. Int J Toxicol.. 2015 Jul-Aug;34:308-317.
Crossref Google Scholar
66

Tummala R, Kavtaradze A, Gupta A, Ghosh RK. Specific antidotes against direct oral anticoagulants: a comprehensive review of clinical trials data. Int J Cardiol.. 2016;214:292-298.
Crossref Google Scholar
67

Frontera JA, Gordon E, Zach V, et al. Reversal of coagulopathy using prothrombin complex concentrates is associated with improved outcome compared to fresh frozen plasma in warfarin-associated intracranial hemorrhage. Neurocrit Care.. 2014;21:397-406.
Crossref Google Scholar
68

Goldstein JN, Marrero M, Masrur S, et al. Management of thrombolysis-associated symptomatic intracerebral hemorrhage. Arch Neurol.. 2010;67:965-969.
Crossref Google Scholar
69

Yaghi S, Boehme AK, Dibu J, et al. Treatment and outcome of thrombolysis-related hemorrhage. JAMA Neurol.. 2015;72:1451.
Crossref Google Scholar
70

Chang A, Llinas EJ, Chen K, Llinas RH, Marsh EB. Shorter intensive care unit stays? Stroke.. 2018 Jun;49:1521-1524.
Crossref Google Scholar
71

Yaghi S, Willey JZ, Cucchiara B, et al. Treatment and outcome of hemorrhagic transformation after intravenous alteplase in acute ischemic stroke a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke.. 2017;48:e343-e361.
Crossref Google Scholar
72

Wilson D, Seiffge DJ, Traenka C, et al. Outcome of intracerebral hemorrhage associated with different oral anticoagulants. Neurol Am Acad Neurol.. 2017;88:1693-1700.
Google Scholar
73

Boulouis G, Morotti A, Pasi M, Goldstein JN, Gurol ME, Charidimou A. Outcome of intracerebral haemorrhage related to non-vitamin K antagonists oral anticoagulants versus vitamin K antagonists: a comprehensive systematic review and meta-analysis. J Neurol Neurosurg Psychiatry.. 2018;89:263-270.
Crossref Google Scholar
74

Inohara T, Xian Y, Liang L, et al. Association of intracerebral hemorrhage among patients taking non-vitamin K antagonist vs vitamin K antagonist oral anticoagulants with in-hospital mortality. JAMA.. 2018;319:463.
Crossref Google Scholar
Brain Hemorrhages
Volume 1 Issue 1,
March 2020
Pages 89-94
DOI: 10.1016/j.hest.2020.01.001
Cite this article:
Morotti A, Goldstein JN. Anticoagulant-associated intracerebral hemorrhage. Brain Hemorrhages, 2020, 1(1): 89-94. https://doi.org/10.1016/j.hest.2020.01.001

60

Views

0

Downloads

23

Crossref

0

Web of Science

20

Scopus

Altmetrics
Published: 23 January 2020
© 2020

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Return